Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.

Interstitial lung disease Non–small cell lung cancer Oligometastatic Reirradiation Stereotactic body radiation therapy Ultracentral

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
07 2021
Historique:
received: 03 03 2021
revised: 02 04 2021
accepted: 07 04 2021
pubmed: 27 4 2021
medline: 10 8 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Stereotactic body radiation therapy (SBRT) is an effective and well-tolerated treatment for medically inoperable patients with early stage NSCLC. SBRT is a noninvasive treatment involving the delivery of ablative radiation doses with high precision in the course of a few treatments. Relative to conventionally fractionated radiation, SBRT achieves superior local control and survival. SBRT use has increased dramatically in the past 15 years and is currently considered the standard of care in cases of inoperable early stage NSCLC. It is being increasingly applied to more complex patient populations at higher risk of treatment-related toxicity. In these more complex patients, there is an increasing need to balance patient and treatment factors in selecting the optimal patients for SBRT. Here, we review several challenging clinical scenarios often encountered in thoracic multidisciplinary tumor boards.

Identifiants

pubmed: 33901637
pii: S1556-0864(21)02112-2
doi: 10.1016/j.jtho.2021.04.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1085

Informations de copyright

Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.

Auteurs

Neal Andruska (N)

Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St Louis, Missouri.

Hayley B Stowe (HB)

Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St Louis, Missouri.

Cathryn Crockett (C)

Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.

Wei Liu (W)

Division of Radiation Oncology, Western University, London, Ontario, Canada.

David Palma (D)

Division of Radiation Oncology, Western University, London, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Corinne Faivre-Finn (C)

Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.

Shahed N Badiyan (SN)

Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St Louis, Missouri. Electronic address: sbadiyan@wustl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH